Key facts
- LabGenius Therapeutics’s last known valuation is $85.9M (Jul 2025).
- It has raised $93.4M; the latest was Later Stage VC ($13.5M) in Jul 2025.
- Notable investors include Innovate UK, Lux Capital, Felicis, Octopus Ventures, Kevin Moore — 35 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 35 names
- ·Watchlist + deal alerts for LabGenius Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for LabGenius Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LabGenius Therapeutics
Developer of next-generation protein-based therapeutics designed to address unmet needs like inflammatory bowel disease. The company's therapeutics engineer protein drugs properties, such as protease stability and tissue penetration, using their smart robotic platform to design, conduct, and critically learning from its experiments, enabling physicians to get access to protein therapeutics that are developed using robotic automation, synthetic biology, and advanced machine learning.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2012
- Employees
- 66
- Website
- labgeniustx.com/
- Ownership
- Privately Held (backing)
LabGenius Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LabGenius Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LabGenius Therapeutics in its N-PORT filings yet. We sweep new filings monthly.